China Pharma Holdings (CPHI) Net Income towards Common Stockholders Growth (1y) (2011 - 2026)
China Pharma Holdings (CPHI) Net Income towards Common Stockholders Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.87 Bn | 42.91 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.00 Bn | 39.35 Bn | 2.15 Bn | -304.98% |
| 3 | Zoetis | 31.59 Bn | 29.92 Bn | 1.05 Bn | -5.04% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -17.29% |
| 5 | United Therapeutics | 22.15 Bn | 19.49 Bn | 683.80 Mn | 7.59% |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | -2,482.61% |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 34.33% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 390.91% |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | China Pharma Holdings | 41.94 Mn | 41.64 Mn | 83,566.00 | -175.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.52% |
| Dec 31, 2025 | 0.19% |
| Sep 30, 2025 | 41.72% |
| Jun 30, 2025 | 63.26% |
| Mar 31, 2025 | 17.82% |
| Dec 31, 2024 | 0.63% |
| Sep 30, 2024 | -43.76% |
| Jun 30, 2024 | -142.51% |
| Mar 31, 2024 | -100.83% |
| Dec 31, 2023 | 2.53% |
| Sep 30, 2023 | 1.67% |
| Jun 30, 2023 | 33.25% |
| Mar 31, 2023 | 53.77% |
| Dec 31, 2022 | -28.90% |
| Sep 30, 2022 | 4.34% |
| Jun 30, 2022 | -7.72% |
| Mar 31, 2022 | -34.17% |
| Dec 31, 2021 | 18.88% |
| Sep 30, 2021 | 18.14% |
| Jun 30, 2021 | -6,418.56% |